Short answer: the label names three maintenance dosages, and reaching goal weight is not one of the things that changes them
Zepbound has exactly three approved maintenance dosages for weight management: 5 mg, 10 mg or 15 mg once weekly. Hitting your goal weight does not move you onto a different one, because the prescribing information contains no instruction that begins "after goal weight". The only dose change it describes in that direction is this sentence from section 2.1: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." Two strengths are ruled out in writing. The starting dose is excluded by name, "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage", and section 2.2 lists only 5 mg, 10 mg and 15 mg, which leaves 7.5 mg and 12.5 mg as escalation steps rather than named destinations.
The six strengths, sorted into the two groups the label actually uses
Zepbound is supplied in six strengths, and most pages present them as one ladder with a finish line at the top. The label does not treat them that way. Section 2.1 describes the climb, section 2.2 names the destinations, and the two lists are not the same list.
| Strength | What the prescribing information calls it |
|---|---|
| 2.5 mg | Treatment initiation only. "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." |
| 5 mg | A recommended maintenance dosage for weight reduction and long-term maintenance. |
| 7.5 mg | An available strength and an escalation step. Not named in the list of recommended maintenance dosages. |
| 10 mg | A recommended maintenance dosage. Also one of the two dosages approved for obstructive sleep apnea. |
| 12.5 mg | An available strength and an escalation step. Not named in the list of recommended maintenance dosages. |
| 15 mg | A recommended maintenance dosage, and the maximum dosage for all indications. |
This matters for a specific group of people: anyone who reached goal weight on 7.5 mg or 12.5 mg and has been told, or has read, that their current dose is now their maintenance dose. It can be the dose a prescriber decides to continue, and prescribers routinely make that call. What it is not is a dosage the label lists under "Recommended Maintenance Dosage". If you want to know which of the two your prescription is, that is a one line question for the person who writes it.
The trial that was built to answer this exact question
SURMOUNT-4 is the only phase 3 tirzepatide trial designed around what happens after the weight comes off. Everyone took tirzepatide openly for 36 weeks at their maximum tolerated dose, 10 mg or 15 mg, and lost a mean of 20.9%. At that point 670 people were randomised: half carried on, half switched to placebo, for another 52 weeks. The published results run to week 88.
| Measured from week 36, the point where the weight was already off | Continued tirzepatide | Switched to placebo |
|---|---|---|
| Mean weight change, week 36 to week 88 | a further 5.5% lost | 14.0% regained |
| Kept at least 80% of the weight lost during the first 36 weeks | 89.5% | 16.6% |
| Mean total weight change, week 0 to week 88 | 25.3% | 9.9% |
Read what that trial did and did not test. It compared an effective dose against nothing. It did not compare 15 mg against 10 mg against 5 mg as maintenance strategies after goal weight, and no published phase 3 trial has. So the honest answer to "which maintenance dose holds weight best" is that the comparison has not been run. What has been established is the gap between continuing and stopping, and it is large.
Why there is no separate maintenance phase in the label
The indication itself is the clue. Section 2.2's heading is "Weight Reduction and Long-Term Maintenance", and the same three dosages sit under both halves of it. The document is not written as a weight loss course followed by a different maintenance course. It is written as one ongoing treatment, which is also how the SURMOUNT-4 result reads.
The three inputs your prescriber is working from
This page does not tell you what dose to be on, and no web page should. What it can do is show you the inputs the label puts in front of the person who decides, so that the appointment is about your data rather than about definitions.
- Treatment response. Section 2.1: "Consider treatment response and tolerability when selecting the maintenance dosage." At goal weight, response stops meaning weekly loss and starts meaning stability.
- Tolerability. The same sentence, and then the explicit permission to go down: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage."
- The step rule still applies in both directions. Escalation moves in 2.5 mg increments after at least 4 weeks on the current dose. Steady-state plasma concentrations arrive after 4 weeks of weekly dosing, which is why a dose change is judged over weeks and not over one injection.
If a lower maintenance dosage is on the table, the thing that usually settles it is not an opinion but a record: what the weight did over the last eight weeks, which side effects were still happening and how they lined up with injection day. For the mechanics of a step change and the published trade-off at each strength, see why the Zepbound dose gets increased.
What to bring to the appointment where this gets decided
Three things turn a vague "I think I am ready to come down" into a decision:
- A dose history with dates, so the weeks at the current strength are a fact rather than an estimate.
- A weight trend over at least eight weeks, because a maintenance question is about the shape of a line, not about one morning's number.
- Side effects logged against the dose and the day they happened, which is what the tolerability half of section 2.1 is asking about.
That is exactly the record a GLP-1 tracker exists to produce. Jabby keeps doses, dates, injection sites and side effects in one timeline, so the answer to "how long have you been on this dose" is a date rather than a guess.
Frequently asked questions
Is 7.5 mg a maintenance dose of Zepbound?
Not in the sense the label uses. Section 2.2 lists 5 mg, 10 mg and 15 mg as the recommended maintenance dosages for weight reduction and long-term maintenance, and 7.5 mg is not among them. It is a real strength and a real escalation step, and a prescriber can continue it, but it is not one of the three the document names. The same applies to 12.5 mg.
Do I lower my dose once I reach my goal weight?
There is no such instruction in the label. The only route down it describes is tolerability: "If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage." Whether reaching goal weight changes anything for you is a prescriber decision, not a labelled step.
What happens if I stop once I am at goal?
In SURMOUNT-4 the group that switched to placebo after 36 weeks regained a mean of 14.0% of body weight over the following 52 weeks, and only 16.6% kept at least 80% of what they had lost, against 89.5% of those who continued.
Can I stay on 5 mg forever?
5 mg is a recommended maintenance dosage, so it is one of the three the label names. In SURMOUNT-1 the 5 mg group's mean weight change at 72 weeks was 15.0%, against 19.5% at 10 mg and 20.9% at 15 mg, so the strengths are not equivalent on average. Which one suits you is the conversation in the section above.
Is the maximum dose the best maintenance dose?
15 mg is the maximum dosage, not a default. The label's instruction is to consider response and tolerability when selecting the maintenance dosage, and the severe gastrointestinal adverse reaction rate in the pooled trials rose with dose, 1.7% at 5 mg, 2.5% at 10 mg and 3.1% at 15 mg, against 1% on placebo.
How long should a new maintenance dose be given before judging it?
Pharmacokinetically, steady-state concentrations are reached after 4 weeks of once weekly dosing, and the escalation rule itself allows an increase only after at least 4 weeks on the current dose. Four weeks is the unit the document works in.
Related reading
- Why increase the Zepbound dose?, with what each step up buys and what it costs
- How long does Zepbound take to work?, for the three clocks that get mixed together
- Long-term side effects of Zepbound, for how far the evidence runs on staying on it
- How do you reduce the side effects of Zepbound?, including the lower maintenance dosage lever
- Zepbound reviews, patient ratings against trial data
- GLP-1 tracker app, for keeping the dose history this decision runs on
Sources
- ZEPBOUND (tirzepatide) US prescribing information, Eli Lilly and Company. Section 2.1 for the escalation schedule, the 2.5 mg exclusion and the tolerability sentence, section 2.2 for the three recommended maintenance dosages and the 15 mg maximum, section 3 for the six strengths, section 5.2 for severe gastrointestinal reaction rates by dose, section 12.3 for steady state.
- ZEPBOUND label on DailyMed, US National Library of Medicine, for an independently hosted copy of the same label.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID 38078870. Trial registration NCT04660643. Source of the 36 week lead-in, the 20.9% lead-in reduction, and the week 36 to 88 figures.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024. Source of the 15.0%, 19.5% and 20.9% figures at 72 weeks.
- Zepbound dosage information for healthcare providers, Eli Lilly and Company, which repeats the three maintenance dosages and the 2.5 mg exclusion.
This page summarises published prescribing information and peer-reviewed trial results for general education. It is not medical advice and it contains no dosing recommendation. Dose selection, including whether to change a dose after reaching a goal weight, belongs to your prescriber. Never start, stop or change a prescribed medicine on the basis of a web page.
Jabby is free on the App Store and keeps every dose, date and side effect on one timeline, so the weeks at your current strength are a record rather than a recollection.